Lucid Diagnostics (NASDAQ:LUCD) Rating Reiterated by Needham & Company LLC

Lucid Diagnostics (NASDAQ:LUCD)‘s stock had its “buy” rating restated by Needham & Company LLC in a report issued on Wednesday, Benzinga reports. They currently have a $2.50 price objective on the stock. Needham & Company LLC’s target price indicates a potential upside of 208.68% from the company’s current price.

Lucid Diagnostics Stock Down 18.2 %

NASDAQ:LUCD opened at $0.81 on Wednesday. The stock’s fifty day moving average is $1.28 and its two-hundred day moving average is $1.33. Lucid Diagnostics has a 52 week low of $0.81 and a 52 week high of $1.85. The stock has a market capitalization of $39.07 million, a price-to-earnings ratio of -0.64 and a beta of 1.73.

Lucid Diagnostics (NASDAQ:LUCD) last released its quarterly earnings results on Tuesday, March 26th. The company reported ($0.26) EPS for the quarter. Lucid Diagnostics had a negative return on equity of 8,334.14% and a negative net margin of 2,169.07%. The firm had revenue of $1.04 million for the quarter. During the same quarter last year, the business earned ($0.22) EPS. On average, sell-side analysts expect that Lucid Diagnostics will post -0.89 EPS for the current fiscal year.

Institutional Trading of Lucid Diagnostics

Several hedge funds have recently modified their holdings of the stock. Luminus Management LLC raised its stake in shares of Lucid Diagnostics by 2.7% in the second quarter. Luminus Management LLC now owns 878,378 shares of the company’s stock valued at $1,221,000 after acquiring an additional 23,078 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Lucid Diagnostics by 11.3% in the third quarter. Vanguard Group Inc. now owns 319,366 shares of the company’s stock valued at $489,000 after acquiring an additional 32,305 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Lucid Diagnostics by 245.3% in the second quarter. Geode Capital Management LLC now owns 143,465 shares of the company’s stock valued at $199,000 after acquiring an additional 101,922 shares in the last quarter. BlackRock Inc. raised its stake in shares of Lucid Diagnostics by 18.7% in the first quarter. BlackRock Inc. now owns 67,565 shares of the company’s stock valued at $227,000 after acquiring an additional 10,636 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of Lucid Diagnostics in the second quarter valued at $87,000. 74.01% of the stock is currently owned by institutional investors and hedge funds.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma (EAC). It offers EsoCheck, a cell collection device to prevent EAC deaths; and EsoGuard, an Esophageal DNA Test.